Contrasting Mateon Therapeutics (OTCMKTS:MATN) and Nemus Bioscience (OTCMKTS:NMUS)

Earnings and Valuation

This table compares Nemus Bioscience and Mateon Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemus Bioscience	N/A	N/A	-$19.19 million	($0.09)	-9.15
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-1.88

Nemus Bioscience is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nemus Bioscience has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Mateon Therapeutics shares are held by institutional investors. 2.7% of Nemus Bioscience shares are held by insiders. Comparatively, 39.2% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Nemus Bioscience and Mateon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemus Bioscience	N/A	N/A	-924.42%
Mateon Therapeutics	N/A	-64.66%	-42.92%

Summary

Mateon Therapeutics beats Nemus Bioscience on 7 of the 8 factors compared between the two stocks.

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.